All News

A trend towards improved progression-free survival was not noted when pembrolizumab plus sacituzumab govitecan was used to treat patients with HR+ breast cancer.

Either telehealth or in-person recipes of palliative care did not impact the quality of life outcomes for patients with advanced non–small cell lung cancer.

The combination of perioperative chemotherapy plus FLOT improved overall survival vs neoadjuvant chemoradiation in patients with resectable esophageal cancer.

Osimertinib may become a new standard of care for those with EGFR-mutant NSCLC, according to Suresh S. Ramalingam, MD, FACP, FASCO.

Data from the ADRIATIC trial show consistent PFS and OS benefits with durvalumab across predefined limited-stage small cell lung cancer subgroups.

Phase 3 findings show the benefit of immunotherapy before surgery in those with macroscopic stage III node-positive melanoma.

The CARACO study shows that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Triplet therapies containing belantamab mafodotin may fulfill an unmet need for patients with multiple myeloma following the first relapse.

Increased PFS was noted with abemaciclib plus fulvestrant vs fulvestrant alone in hormone receptor–positive, HER2-negative advanced breast cancer after disease progression on a CDK4/6 inhibitor and endocrine therapy.

CHAARTED2 trial showed an improved progression-free survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, abiraterone acetate, and prednisone.

The addition of tucidinostat to R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2, according to interim analysis results.

Relapse-free survival was improved when anthracycline combo was used to treat MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer.

A PFS benefit with adagrasib was observed across all key patient subgroups in the phase 3 KRYSTAL-12 trial.

Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.

Adjuvant sacituzumab govitecan demonstrated a complete response, but its future in bladder cancer is uncertain after a recent protocol amendment.

Treatment with DFF332 appears to be safe and tolerable across all dose levels, according to Sumanta Kumar Pal, MD.

Neoadjuvant avelumab plus cisplatin yielded high event-free survival in muscle-invasive urothelial carcinoma.

Subcutaneous amivantamab proved noninferior vs intravenous administration in EGFR-mutated non–small cell lung cancer.

Subgroup findings suggest a PFS benefit with the addition of encorafenib/binimetinib in patients with liver metastases.

Updated MARIPOSA results found improves progression-free survival in patients with high-risk EGFR-mutant advanced non-small cell lung cancer when treated with amivantimab/lazertinib.

Brentuximab vedotin led to unprecedented progression-free survival for patients with classical Hodgkin lymphoma.

A reduction in splenomegaly was observed when the combination of pelabresib plus ruxolitinib was used to treat patients with myelofibrosis.

Ponatinib remains a safe treatment for patients with chronic-phase chronic myeloid leukemia.

Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.

Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.

An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.

The FDA has set a new Prescription Drug User Fee Act date of November 9, 2024, for zolbetuximab in this gastric cancer population.

The benefit-risk profile of asciminib may change the chronic myeloid leukemia treatment paradigm, according to Jorge E. Cortes, MD.

Lorlatinib may show “unprecedented” improvements in outcomes for those with advanced ALK-positive NSCLC, according to Benjamin J. Solomon, MBBS, PhD.